Cerebrolysin
Also known as: Porcine brain peptide preparation · FPF-1070
A complex mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue, studied extensively in cognitive decline and post-stroke recovery research.
Cerebrolysin is a standardised porcine-brain peptide preparation licensed in several jurisdictions for stroke and dementia; parenteral administration; strong Cochrane evidence base.
Evidence tier: A — ≥1 RCT + meta-analysis or approved clinical use
- Category
- Neuroprotection
- Half-life
- Multiple components with varied pharmacokinetics
Section 1
Overview
Cerebrolysin is not a single peptide but a standardised preparation of low-molecular-weight neuropeptides and free amino acids derived from enzymatic digestion of porcine brain tissue. It has been used as a prescription parenteral neurotrophic preparation for several decades in many jurisdictions for indications including stroke recovery, dementia, and traumatic brain injury.
The preparation contains active fragments that mimic the action of endogenous neurotrophic factors such as BDNF, NGF, and GDNF, producing pleiotropic neuroprotective and neurotrophic effects in published research.
Because Cerebrolysin is a complex biological preparation rather than a single chemical entity, much of the published research is clinical and outcome-focused rather than mechanistically reductive — though substantial mechanistic work has been done in cell-culture and animal models.
Section 2
Discovery & History
- Developed in the 1950s by the Austrian pharmaceutical company Ever Neuro Pharma (originally Nycomed / EBEWE), with the manufacturing process refined over subsequent decades to standardise the bioactive component profile of the porcine-brain digest.
- Manufactured by enzymatic proteolytic digestion of purified porcine brain protein under standardised conditions, yielding a peptide-amino-acid mixture in which approximately 25% of the mass is short bioactive peptides <10 kDa and the remainder is free amino acids.
- Subject to a substantial body of clinical trial work in vascular dementia, Alzheimer's disease, acute ischaemic stroke, and traumatic brain injury — primarily from European (Austrian, German, Russian) and Asian (Chinese, Korean, Indian) research centres accumulated over five decades.
- The Cochrane systematic-review process has looked at Cerebrolysin repeatedly, most substantively in vascular dementia and acute stroke; the reviews report modest but statistically significant effects on cognitive and functional endpoints.
- No entry for Cerebrolysin was found in the electronic medicines compendium (emc) on 17 October 2026. Vidal.ru lists Cerebrolysin as a registered product in Russia (registration number ЛП-№(009552)-(РГ-RU)).
Section 3
Mechanism of Action
- 1Mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF) through low-molecular-weight peptide fragments that act as pharmacological analogues of the parent neurotrophins at their cognate receptors.
- 2Promotes neuronal survival under ischaemic and oxidative stress in cell-culture and animal models, with the mechanistic literature identifying reductions in apoptotic marker expression (caspase-3 activation, cytochrome-c release) as central to the effect.
- 3Modulates amyloid-beta processing in research models of Alzheimer-type pathology — reported reductions in amyloid-beta 42 production and enhanced clearance in transgenic mouse models.
- 4Anti-apoptotic effects via stabilisation of the mitochondrial apoptotic pathway — preservation of mitochondrial membrane potential under ischaemic and excitotoxic insults in in-vitro models.
- 5Modulation of microglial activation phenotype (M1/M2 balance shift) and measurable reduction of pro-inflammatory neuroinflammatory mediators (TNF-α, IL-1β, IL-6) in ischaemic and traumatic injury models.
- 6Positive modulation of adult hippocampal neurogenesis — increased BrdU-labelled dentate-gyrus neurogenesis in aged and post-injury rodent models, providing a plausible substrate for the observed cognitive-recovery effects in clinical work.
- 7Enhancement of glutamatergic-inhibitory synaptic balance and dendritic-spine density in cortical and hippocampal preparations — a synaptic-plasticity contribution to the pleiotropic effect profile.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Improvement in cognitive scores (Mini-Mental State Examination, ADAS-cog) in published vascular-dementia trials — the strongest and most-replicated clinical evidence base.
- 2Faster recovery of neurological function (NIHSS improvement, Barthel Index recovery) after acute ischaemic stroke in randomised research when Cerebrolysin is added to standard-of-care rehabilitation.
- 3Reduction in apoptotic neuronal loss and improved histological outcomes in traumatic brain injury and controlled cortical impact research models.
- 4Long history of clinical use in many jurisdictions provides extensive real-world safety and tolerability data across paediatric, adult, and elderly populations — an unusual asset for a peptide-based therapeutic.
- 5Pleiotropic mechanism — multiple bioactive components hitting multiple pathways rather than a single target — providing a plausible advantage in polyaetiological conditions like vascular dementia and post-stroke recovery.
- 6Reported effects on post-stroke depression and mood alongside the cognitive endpoints, potentially reflecting the BDNF-mimetic components of the mixture.
- 7Improvement in ADL (activities of daily living) functional metrics in TBI cohorts — a patient-relevant endpoint that not every neuroprotective intervention delivers.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Intravenous infusion (clinical use in approving jurisdictions) | 10, 30 or 60 mL per infusion (three dose arms), doses used in Alvarez et al., 2006 (PMID 16420392), a trial in mild to moderate Alzheimer's disease | 5 days per week for the first 4 weeks, then two infusions per week for 8 weeks | 12 weeks of infusions; outcomes assessed to week 24 | Alvarez et al., 2006 (PubMed 16420392) |
Note: No entry for Cerebrolysin was found in the electronic medicines compendium (emc) on 17 October 2026. This information is provided for educational reference only. The doses shown are those tested in one trial, not recommendations.
Section 6
Administration Routes
- Intravenous infusion is the standard route in approved clinical use, with the preparation diluted in saline.
- Intramuscular administration is used in some protocols where infusion access is impractical, at reduced per-dose volumes to accommodate the injection-volume limit.
- Oral administration is not viable — the peptide components are efficiently degraded by gastrointestinal proteases and the amino-acid components carry no meaningful oral bioactivity.
- Intranasal formulations have been explored preclinically but are not the standard route in approved clinical practice.
Section 7
Safety Profile
Commonly reported
- · Transient sensations of warmth or flushing during infusion — reported at a low but characteristic frequency in clinical use; usually self-limiting within minutes of infusion completion.
- · Mild injection-site reactions in intramuscular administration — local irritation, transient erythema, mild tenderness.
- · Headache or dizziness in a minority of subjects, more commonly with faster infusion rates.
- · Occasional gastrointestinal upset (nausea, appetite change) during a course, typically resolving without intervention.
- · Transient increase in blood pressure or heart rate during infusion in some subjects — the summary of product characteristics in approving jurisdictions advises slow infusion in cardiovascularly susceptible patients.
Rare / theoretical
- · Hypersensitivity reactions to the porcine-derived preparation — genuine allergic responses are uncommon but documented; skin-test protocols exist in some clinical settings for atopic patients.
- · Theoretical infectious-disease considerations associated with animal-derived biologics; managed in licensed manufacture by extensive purification, viral inactivation, and standardised source-herd controls under GMP.
- · Rare reports of seizure precipitation in status-epilepticus patients (a listed contraindication) — Cerebrolysin should not be used during active status epilepticus.
- · Theoretical interaction with MAO inhibitors given the free-amino-acid content of the preparation — labelling in some jurisdictions advises caution with concomitant MAO-inhibitor therapy.
Contraindications
- · No entry for Cerebrolysin was found in the electronic medicines compendium (emc) on 17 October 2026.
- · Status epilepticus (per labelling in approving jurisdictions)
- · Severe renal impairment (per labelling)
- · Known hypersensitivity to porcine-derived proteins
Section 8
UK & EU Regulatory Context
United Kingdom
No entry for Cerebrolysin was found in the electronic medicines compendium (emc) on 17 October 2026. The emc is not a complete record of UK authorisations, so check the MHRA Products database.
European Union
Not on the EMA's list of centrally authorised medicines (checked 17 October 2026); any national authorisations in individual EU states were not checked.
Section 9
Clinical Studies Summary
Cerebrolysin in vascular dementia — meta-analysis
Cochrane-style systematic-review-and-meta-analysis pooling multiple randomised placebo-controlled trials of Cerebrolysin in vascular dementia populations, reporting cognitive-score improvement (ADAS-cog, MMSE) versus placebo with modest but statistically significant effect sizes. The review notes methodological heterogeneity across included trials and identifies the ongoing need for larger contemporary Western-standard RCTs.
Read studyCerebrolysin in acute ischaemic stroke
Multicentre randomised study (CASTA trial) in acute ischaemic stroke reporting accelerated neurological recovery (NIHSS improvement) at 90 days in subjects receiving Cerebrolysin adjunct to standard-of-care thrombolysis and rehabilitation, with the effect strongest in the moderate-severity stroke stratum.
Read studyMechanistic dissection of Cerebrolysin's anti-amyloid effects
Animal-model work in APP/PS1 double-transgenic mice reporting reduced amyloid-beta 42 accumulation, preserved dendritic spine density, and improved spatial-learning performance (Morris water maze) in Cerebrolysin-treated cohorts versus vehicle controls, linking a molecular pathology-modification signal to a behavioural cognitive endpoint.
Cerebrolysin in traumatic brain injury — CAPTAIN trial programme
Multicentre randomised trial programme investigating Cerebrolysin in moderate-to-severe TBI populations, reporting improved functional recovery on the Glasgow Outcome Scale-Extended and improved cognitive endpoints at 90 days across the CAPTAIN I and CAPTAIN II arms.
Cerebrolysin adjunct to standard-of-care in Alzheimer's disease
Randomised controlled trial in mild-to-moderate Alzheimer's disease evaluating Cerebrolysin as adjunct to donepezil, reporting improved cognitive and global-impression scores at 24 weeks versus donepezil alone, with a subsequent open-label extension supporting durability of the differential.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Cerebrolysin for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Cerebrolysin from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: this page is educational. Regulation 46(1) of the Human Medicines Regulations 2012 prohibits selling or supplying an unauthorised medicinal product, and some compounds on this site, such as semaglutide, are authorised prescription-only medicines in the UK.